Investigation of usability of combination therapy with S-1 plus panitumumab in patients with KRAS wild type unresectable advanced and recurrent colorectal cancer, who had previously received on fluoropyrimidine, oxaliplatin and irinotecan: phase II study.
Phase of Trial: Phase II
Latest Information Update: 03 May 2017
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Panitumumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 30 Apr 2017 Status changed from active, no longer recruiting to completed.
- 30 May 2012 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
- 30 May 2012 Actual initiation date (Apr 2012) added as reported by University Hospital Medical Information Network - Japan.